1022 related articles for article (PubMed ID: 24126697)
41. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
42. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
43. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
44. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
45. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
[TBL] [Abstract][Full Text] [Related]
46. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
47. MDM2/MDMX inhibitor peptide: WO2008106507.
Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
[TBL] [Abstract][Full Text] [Related]
48. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
[TBL] [Abstract][Full Text] [Related]
49. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.
Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L
Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062
[TBL] [Abstract][Full Text] [Related]
50. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
51. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
52. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
54. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
[TBL] [Abstract][Full Text] [Related]
55. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
57. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
58. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells.
Proietti S; Cucina A; Dobrowolny G; D'Anselmi F; Dinicola S; Masiello MG; Pasqualato A; Palombo A; Morini V; Reiter RJ; Bizzarri M
J Pineal Res; 2014 Aug; 57(1):120-9. PubMed ID: 24920214
[TBL] [Abstract][Full Text] [Related]
59. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
60. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.
Zhang YF; Zhang BC; Zhang AR; Wu TT; Liu J; Yu LF; Wang WX; Gao JF; Fang DC; Rao ZG
Oncol Rep; 2013 Oct; 30(4):1989-95. PubMed ID: 23933826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]